| parainfluenza virus | <virology> Species of the Paramyxoviridae, there are four types. Type 1 is also called Sendai virus or Haemagglutinating virus of Japan (HVJ) and the inactivated form is used to bring about cell fusion. Types 2-4 cause mild respiratory infections in humans. (18 Nov 1997) |
|---|---|
| parainfluenza virus 1, human | The type species of paramyxovirus also called haemadsorption virus 2 (ha2), which causes laryngotracheitis in humans, especially children. (12 Dec 1998) |
| parainfluenza virus 2, human | A species of rubulavirus associated particularly with acute laryngotracheitis (croup) in children aged 6 months to 3 years. (12 Dec 1998) |
| parainfluenza virus 3, human | A species of paramyxovirus frequently isolated from small children with pharyngitis, bronchitis, and pneumonia. (12 Dec 1998) |
| parainfluenza viruses | Virus's of the genus Paramyxovirus, of four types: type 1 (haemadsorption virus type 2), which includes sendai virus, causes acute laryngotracheitis in children and occasionally adults; type 2 (croup-associated virus) is associated especially with acute laryngotracheitis or croup in young children and minor upper respiratory infections in adults; type 3 (haemadsorption virus type 1; shipping fever virus) has been isolated from small children with pharyngitis, bronchiolitis, and pneumonia, and causes occasional respiratory infection in adults; bovine strains have been isolated from cattle with shipping fever, and the virus has also been isolated from sheep; type 4 has been isolated from a very few children with minor respiratory illness. (05 Mar 2000) |
| aids vaccines | Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent aids. Some vaccines containing antigens are recombinantly produced. (12 Dec 1998) |
| bacterial vaccines | Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. (12 Dec 1998) |
| cancer vaccines | Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumour cells as the source of antigens, or using tumour-specific antigens, often recombinantly produced. (12 Dec 1998) |
| vaccines | Vaccines are microbial preparations of killed or modified microorganisms which can stimulate an immune response in the body in order to prevent future infection with similar microorganism. The smallpox vaccine has totally eliminated the smallpox disease from our planet. (12 Dec 1998) |
| vaccines, attenuated | Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. (12 Dec 1998) |
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| vaccines, conjugate | Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection. (12 Dec 1998) |
| vaccines, DNA | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. (12 Dec 1998) |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
| vaccines, synthetic | Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. (12 Dec 1998) |